Evidence map›Paper›PMID 26047500›Full record

ArticlePloS one2015

Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment.

Amaly Nokkari, Tarek H Mouhieddine, Muhieddine M Itani, Wassim Abou-Kheir, Georges Daoud, Rui Zhu, Yehia Mechref, Yehia Meshref, Jihane Soueid, Moustafa Al Hariri and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Amaly NokkariFaculty of Medicine, Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Tarek H MouhieddineFaculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Muhieddine M ItaniFaculty of Medicine, Saint George University of London, Nicosia, Cyprus.
Wassim Abou-KheirFaculty of Medicine, Department of Anatomy, Cell Biology and Physiology, American University of Beirut, Beirut, Lebanon.
Georges DaoudFaculty of Medicine, Department of Anatomy, Cell Biology and Physiology, American University of Beirut, Beirut, Lebanon.
Rui ZhuDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, United States of America.
Yehia Mechref
Yehia MeshrefDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, United States of America.
Jihane SoueidFaculty of Medicine, Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Moustafa Al HaririFaculty of Medicine, Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Stefania MondelloUniversity of Messina, Department of Neurosciences, Messina, Italy.
Ayad A JaffaFaculty of Medicine, Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Firas KobeissyFaculty of Medicine, Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
American University of Beirut · LBTexas Tech University · USAmerican University of Beirut Medical Center · LBUniversity of Messina · ITUniversity of Nicosia · CY

Funding

MECHANISMS OF VASCULAR DISEASE IN DIABETESR01HL077192 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JAFFA, AYAD A · 2006 to 2017
$3.4M
KALLIKREIN AND VASCULAR DISEASE RISK IN DIABETESR01HL087986 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI JAFFA, AYAD A · 2008 to 2011
$1.3M
NHLBI NIH HHS HL077192NHLBI NIH HHS HL087986NHLBI NIH HHS R01 HL077192NHLBI NIH HHS R01 HL087986
6 · The paper itself

Abstract

Traumatic Brain Injury (TBI) is the result of a mechanical impact on the brain provoking mild, moderate or severe symptoms. It is acknowledged that TBI leads to apoptotic and necrotic cell death; however, the exact mechanism by which brain trauma leads to neural injury is not fully elucidated. Some studies have highlighted the pivotal role of the Kallikrein-Kinin System (KKS) in brain trauma but the results are still controversial and inconclusive. In this study, we investigated both the expression and the role of Bradykinin 1 and 2 receptors (B1R and B2R), in mediating neuronal injury under chemical neurotoxicity paradigm in PC12 cell lines. The neuronal cell line PC12 was treated with the apoptotic drug Staurosporine (STS) to induce cell death. Intracellular calcium release was evaluated by Fluo 4-AM staining and showed that inhibition of the B2R prevented calcium release following STS treatment. Differential analyses utilizing immunofluorescence, Western blot and Real-time Polymerase Chain Reaction revealed an upregulation of both bradykinin receptors occurring at 3h and 12h post-STS treatment, but with a higher induction of B2R compared to B1R. This implies that STS-mediated apoptosis in PC12 cells is mainly conducted through B2R and partly via B1R. Finally, a neuroproteomics approach was conducted to find relevant proteins associated to STS and KKS in PC12 cells. Neuroproteomics results confirmed the presence of an inflammatory response leading to cell death during apoptosis-mediated STS treatment; however, a "survival" capacity was shown following inhibition of B2R coupled with STS treatment. Our data suggest that B2R is a key player in the inflammatory pathway following STS-mediated apoptosis in PC12 cells and its inhibition may represent a potential therapeutic tool in TBI.

Indexed as

AnimalsCell DeathEnzyme InhibitorsKallikrein-Kinin SystemNeuronsPC12 CellsProteomicsRatsReceptor, Bradykinin B1Receptor, Bradykinin B2Signal TransductionStaurosporineTranscriptional ActivationEnzyme InhibitorsReceptor, Bradykinin B1Receptor, Bradykinin B2Staurosporine

Identifiers

PMID26047500
PMCPMC4457722
OpenAlexW2115083872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.